Mr. Littman is responsible for facilitating opportunities for outside investment in stem cell research in California for both CIRM-funded and non CIRM-funded programs by biopharmaceutical strategic partners, equity investors, and disease foundations.

Prior to joining CIRM in 2012, Mr. Littman was a Senior Associate in the Merchant Banking Group at Burrill & Company, a diversified global financial services firm focused on the life sciences industry based in San Francisco.  While at Burrill & Company, Mr. Littman’s responsibilities included both strategic advisory and capital raising assignments for biopharmaceutical companies throughout the U.S. and internationally.

Mr. Littman’s strategic advisory experience includes buy-side and sell-side M&A, as well as in-licensing and out-licensing of both development stage and commercial products.  Prior to joining Burrill & Company in 2009, Mr. Littman worked in the Healthcare Investment Banking group at Thomas Weisel Partners where he focused on strategic advisory assignments and public and private financings. Prior to Thomas Weisel Partners, Mr. Littman worked in the Healthcare Investment Banking group at Deutsche Bank Securities.

Mr. Littman received a Master of Science in Biotechnology with a concentration in Biotechnology Enterprise from The Johns Hopkins University, and a Bachelor of Arts in Molecular, Cellular and Development Biology from the University of Colorado Boulder in 2002.